Ascletis
Aug 13, 2019
GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre
GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
